close 73% van de retail rekeningen verliezen gelden met de handel in CFD`s bij deze aanbieder. Investeringen zijn risicovol en zijn niet geschikt voor alle beleggers. CFD`s zijn complexe instrumenten met een hoog risico om snel gelden te verliezen vanwege het hefboomeffect. 73% van de retail beleggers lijdt verlies bij het handelen in CFD`s met deze aanbieder. Het is belangrijk dat u goed begrijpt hoe CFD`s werken en dat u nagaat of u zich het hoge risico op verlies kunt permitteren.
ZoekenZoeken
Change languageNederlands
Dashboard

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

Home・Aandelen Lijst・Karyopharm Therapeutics Inc
Search

Karyopharm Therapeutics Inc

Gesloten

SectorGezondheidszorg

9.53 3.47

Strong Buy

Prijsupdate 19 feb 2026, 20:59 UTC

BuySell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

9.53

Max

9.53

Belangrijke statistieken

By Trading Economics

Inkomsten

4.1M

-33M

Verkoop

6.1M

44M

EPS

-2.227

Winstmarge

-75.213

Werknemers

279

EBITDA

1.8M

-23M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+72.39% upside

Marktinformatie

By TradingEconomics

Marktkapitalisatie

55M

157M

Vorige openingsprijs

6.06

Vorige sluitingsprijs

9.53

Nieuwssentiment

By Acuity

40%

60%

108 / 351 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

5.9501 / 7.66 Steun & Weerstand

Karyopharm Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

22 feb 2026, 23:55 UTC

Marktinformatie

Gold and Silver Rise Amid Renewed Trade Tensions -- Market Talk

DJ

Lezen

22 feb 2026, 23:53 UTC

Marktinformatie

Japan Activity Data Set to Show Strength, Backed by Fiscal Spending -- Market Talk

DJ

Lezen

22 feb 2026, 23:53 UTC

Marktinformatie

Key China Rates Likely to Be Held Steady for Now -- Market Talk

DJ

Lezen

22 feb 2026, 23:51 UTC

Marktinformatie

Bank of Korea Set to Hold Fire as Inflation Steadies, Risks Linger -- Market Talk

DJ

Lezen

22 feb 2026, 23:35 UTC

Marktinformatie

Oil Falls Amid Prospect That U.S. Strike on Iran Might Be Limited -- Market Talk

DJ

Lezen

22 feb 2026, 23:21 UTC

Winsten

Nickel Industries 2025 Adjusted Ebitda US$283.0 Million

DJ

Lezen

22 feb 2026, 23:20 UTC

Winsten

Nickel Industries 2025 Operating Profit US$126.4 Million

DJ

Lezen

22 feb 2026, 23:19 UTC

Winsten

Nickel Industries 2025 Revenue US$1.65 Billion, Down 5.5% On-Year

DJ

Lezen

22 feb 2026, 23:19 UTC

Winsten

Correct: Nickel Industries 2025 Net Loss US$57.1 Million, Down 66% On-Year

DJ

Lezen

22 feb 2026, 23:18 UTC

Winsten

Nickel Industries Won't Pay a Final Dividend

DJ

Lezen

22 feb 2026, 23:16 UTC

Winsten

Nickel Industries 2025 Net Loss A$57.1 Million, Down 66% On-Year

DJ

Lezen

22 feb 2026, 21:35 UTC

Winsten

Ampol Expects to Start Commissioning of Ultra Low Sulfur Fuels Project in 2Q

DJ

Lezen

22 feb 2026, 21:34 UTC

Winsten

Ampol Says F&I Australia, International Have Begun 2026 Strongly

DJ

Lezen

22 feb 2026, 21:34 UTC

Winsten

Ampol Expects Stage 1 of Fuel Security Services Payment Review Finalized in 1Q

DJ

Lezen

22 feb 2026, 21:33 UTC

Winsten

Ampol Says Lytton Refiner Margin Was US$8.13/bbl in January

DJ

Lezen

22 feb 2026, 21:33 UTC

Winsten

Ampol Recognizes A$89.9 Million Impairment in Carrying Value of Investment in Seaoil

DJ

Lezen

22 feb 2026, 21:28 UTC

Winsten

Ampol Final Dividend A$0.60/Share

DJ

Lezen

22 feb 2026, 21:28 UTC

Winsten

Ampol FY Revenue A$31.37 Billion, Down 10%

DJ

Lezen

22 feb 2026, 21:28 UTC

Winsten

Ampol FY Replacement-Cost Net Profit A$429.2 Million, Up 83%

DJ

Lezen

22 feb 2026, 21:28 UTC

Winsten

Ampol FY Historical-Cost Net Profit A$82.4 Million, Down 33%

DJ

Lezen

21 feb 2026, 14:31 UTC

Acquisities, Fusies, Overnames

Bridgewater Associates' 4Q Buying and Selling -- Barrons.com

DJ

Lezen

21 feb 2026, 05:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

DJ

Lezen

20 feb 2026, 23:12 UTC

Acquisities, Fusies, Overnames

FERC Authorizes TXNM Energy Acquisition by Blackstone Infrastructure

DJ

Lezen

20 feb 2026, 22:12 UTC

Winsten

Equinox Gold: Announces Filing of 2025 Audited Fincl Statements

DJ

Lezen

20 feb 2026, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

DJ

Lezen

20 feb 2026, 21:50 UTC

Marktinformatie

Auto & Transport Roundup: Market Talk

DJ

Lezen

20 feb 2026, 21:23 UTC

Winsten

These Stocks Are Today's Movers: Grail, Corning, Comfort Systems USA, Opendoor, Akamai, Chemours, and More -- Barrons.com

DJ

Lezen

20 feb 2026, 21:20 UTC

Marktinformatie

Century Aluminum Backs Trump's Tariffs After SCOTUS Ruling -- Market Talk

DJ

Lezen

20 feb 2026, 21:01 UTC

Acquisities, Fusies, Overnames

Want to Win the Warner Bros. Discovery Takeover Battle? 'Walk Away Now.' -- Barrons.com

DJ

Lezen

20 feb 2026, 20:38 UTC

Marktinformatie

U.S. Natural Gas Gains Ahead of Chilly Weekend -- Market Talk

DJ

Lezen

Peer Vergelijking

Prijswijziging

Karyopharm Therapeutics Inc Prognose

Koersdoel

By TipRanks

72.39% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 16.67 USD  72.39%

Hoogste 23 USD

Laagste 12 USD

Gebaseerd op 4 Wall Street-analisten die 12-maands prijsdoelen bieden voor Karyopharm Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

4 ratings

4

Buy

0

Hold

0

Sell

Gebaseerd op 4 analisten die aandelenratings hebben gegeven aan Karyopharm Therapeutics Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

5.9501 / 7.66Steun & Weerstand

Korte Termijn

Bullish Evidence

Recent bullish events outweigh bearish events.

Gemiddeld Termijn

Strong Bearish Evidence

All events are bearish.

Lange Termijn

No Evidence

There are no events.

Sentiment

By Acuity

108 / 351 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Andere aandelen uit de sector

LLY

Eli Lilly and Co.

1,008.73

↓-1.37%

JNJ

Johnson and Johnson

242.5

↓-1.77%

ABBV

AbbVie Inc

224.75

↑ +0.24%

NVS

Novartis AG

162.69

↓-0.47%

MRK

Merck & Co Inc.

122.26

↑ +0.39%
help-icon Live chat